FIA
CLDX icon

FNY Investment Advisers’s Celldex Therapeutics CLDX Stock Holding History

FNY Investment Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14
Closed – – 1011
2025
Q3 		$0 Sell
14
-2,393
-99% -$55.5K ﹤0.01% 1266
2025
Q2 		$48K Buy
+2,407
New +$46.9K 0.02% 408
2020
Q4 		– Sell
-2,000
Closed -$29K – 790
2020
Q3 		$29K Buy
+2,000
New +$23.4K 0.01% 277

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FNY Investment Advisers's CLDX Position: Q4 2025 in Review

FNY Investment Advisers sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 14 shares.

FNY Investment Advisers first reported a position in CLDX in Q3 2020 and held it in 3 quarters. The position peaked at $48K in Q2 2025. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • FNY Investment Advisers reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 14 Celldex Therapeutics shares in Q4 2025.
  • FNY Investment Advisers first reported a position in Celldex Therapeutics in Q3 2020 and held it in 3 quarters.
  • FNY Investment Advisers's Celldex Therapeutics position peaked at $48K in Q2 2025.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.